Injectafer® (ferric carboxymaltose)

Injectafer is covered for FDA‑approved iron deficiency anemia indications (patients ≥1 year intolerant or unresponsive to oral iron; adults with non‑dialysis CKD; adults with HF NYHA II/III) and for compendial off‑label use in dialysis‑dependent CKD, with other indications not authorized. Key requirements include age limits (≥1 yr for general IDA; ≥18 yr for CKD and HF), specialty prescribing/consultation for CKD (nephrology/hematology) and HF (cardiology/hematology), documentation of prior oral‑iron failure or qualifying absorption/ESA/cancer criteria for other IDA uses, weight/Hb/ferritin/TSAT‑based dosing and maintenance rules (specified single or two‑dose regimens and HF dosing schema), 12‑month approval duration, and supporting labs/consult notes.

"Clinical notes or consultation reports when specialty consultation is required (nephrology, hematology, cardiology)."